Latest news with #Verzenio
Yahoo
15 hours ago
- Business
- Yahoo
1 Underrated Reason to Buy This Market-Beating Stock
Eli Lilly recently acquired a smaller biotech for its promising investigational pain medication. The company generates strong sales from products outside of diabetes and obesity care. Eli Lilly's portfolio, both within and outside its core area, makes the stock attractive. 10 stocks we like better than Eli Lilly › Eli Lilly (NYSE: LLY) has been one of the top-performing healthcare megacap stocks of the past decade. And in more recent years, particularly over the past five, it's easy to point to the biggest factor driving Eli Lilly's run: The company's work in diabetes and, especially, the weight loss market. Eli Lilly is unquestionably one of the two leaders in this fast-growing field, and it appears to be gaining ground on its biggest competitor, Novo Nordisk. However, a recent move Eli Lilly made reveals an underrated reason why the stock has attractive prospects. Here's what investors should know. On May 27, Eli Lilly announced it would dish out $1 billion in cash to acquire SiteOne Therapeutics, a privately held biotech. The key asset from this transaction is STC-004, a mid-stage investigational non-opioid oral pain medicine. Though there are treatment options for chronic pain, non-opioid ones could become increasingly popular since opioid-based therapies often carry significant side effects. Meanwhile, this market is brand new. In January, Vertex Pharmaceuticals earned approval from the U.S. Food and Drug Administration for Journavx, the first non-opioid oral pain inhibitor. Eli Lilly is looking to make waves in this market with the acquisition of SiteOne Therapeutics. The transaction may or may not pan out. Perhaps STC-004 will flop in upcoming clinical trials. But there's something important to highlight about Eli Lilly that this acquisition brings to light. This move is hardly out of the ordinary for Eli Lilly. One thing that sets it apart from Novo Nordisk is that, while the latter generates more than 90% of its revenue from its diabetes or obesity medicines, Eli Lilly's lineup of drugs features some major blockbusters outside this area. In the first quarter, the company's revenue grew 45% year over year to $12.73 billion. Eli Lilly's cancer drug Verzenio racked up $1.2 billion in sales, up 10% year over year. The company's immunosuppressant, Taltz, generated $762 million in revenue, a 26% increase over the year-ago period. Eli Lilly's sales outside of diabetes and obesity products accounted for almost 28% of its top line. That might not exactly be peak diversification, but Eli Lilly fares better than its eternal rival, Novo Nordisk, in this department. Furthermore, the company's newer products also feature several that fall outside its core area of expertise. These include Kisunla in Alzheimer's disease, Jaypirca in oncology, and Ebglyss, an eczema treatment. The same can be said about Eli Lilly's pipeline. Consider the company's investigational gene therapy for genetic deafness, as well as its several dozen programs in oncology. To be clear, Eli Lilly's diabetes and weight management medicines should continue occupying the role of main growth drivers. In the first quarter, Mounjaro's revenue soared by 113% year over year to $3.8 billion. Zepbound's sales came in at $2.3 billion, representing a 347% increase compared to the first quarter of 2024. Neither has peaked yet. Considering analyst projections for the GLP-1 market, they will continue growing their sales at an incredible clip at least through the end of the decade. And there is more where that came from, too. Eli Lilly is developing newer medicines in this area. The company's investigational oral GLP-1 therapy, orforglipron, recently aced a phase 3 study. According to management, the drugmaker has a total of 11 obesity pipeline candidates. So, Eli Lilly's work in this field will remain one of the major keys to its success. Perhaps it is what will get many investors nowadays interested in the stock. However, Eli Lilly is also a diversified pharmaceutical giant with a strong portfolio of medicines and promising candidates in oncology, immunology, and other areas. So, even with mounting competition in the GLP-1 market, Eli Lilly remains attractive, not just because it is likely to develop better anti-obesity medicines than most of its competitors, but because it is a leader in other markets as well. That's another excellent reason to invest in Eli Lilly and hold on to its shares for a long time. Before you buy stock in Eli Lilly, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Eli Lilly wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $657,385!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $842,015!* Now, it's worth noting Stock Advisor's total average return is 987% — a market-crushing outperformance compared to 171% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of June 2, 2025 Prosper Junior Bakiny has positions in Eli Lilly, Novo Nordisk, and Vertex Pharmaceuticals. The Motley Fool has positions in and recommends Vertex Pharmaceuticals. The Motley Fool recommends Novo Nordisk. The Motley Fool has a disclosure policy. 1 Underrated Reason to Buy This Market-Beating Stock was originally published by The Motley Fool Sign in to access your portfolio
The Advertiser
3 days ago
- Health
- The Advertiser
Blood test-guided treatment cuts breast cancer risk
Treating breast cancer patients with AstraZeneca's experimental pill camizestrant at the first sign of resistance to standard therapies cut the risk of disease progression or death by half, a finding that could be practice changing, experts say. The results, presented at the American Society of Clinical Oncology meeting in Chicago, mark the first use of a blood test called a liquid biopsy to indicate the need for a change in treatment in women with a common form of breast cancer, even before tumour growth can be detected on imaging. The early switch approach in women with hormone receptor-positive, HER2-negative breast cancer resulted in a 56 per cent reduction in the risk of disease progression or death, said Dr Eleonora Teplinsky, an oncologist at Valley-Mount Sinai Comprehensive Cancer Care and an ASCO breast cancer expert. "When patients progress on scans, we're already behind," Teplinsky said at a media briefing. She said an early switch approach, before disease progression, allows doctors "to essentially stay ahead of the curve." Camizestrant is not yet FDA-approved, but Teplinsky said she believes the data will likely result in a new treatment paradigm. The trial involved 3256 patients with advanced hormone receptor-positive, HER2-negative breast cancer, the most common type in which hormones such as oestrogen fuel cancer growth. These cancers lack high levels of HER2, another cancer driver. Women in the trial had at least six months of treatment with aromatase inhibitors that block hormones fueling the cancer, as well as targeted drugs called CDK4/6 inhibitors such as Novartis' Kisqali, Pfizer's Ibrance or Eli Lilly's Verzenio, which block an enzyme that fuels cancer growth. About 40 per cent of patients treated with aromatase inhibitors develop mutations in the oestrogen receptor 1 gene called ESR1 mutations, a sign of early drug resistance. Camizestrant and similar drugs called selective oestrogen receptor degraders, or SERDS, block oestrogen receptor signalling in cancer cells. In the trial, researchers used blood tests to identify 315 patients with signs of early drug resistance and then randomly assigned them to either switch to camizestrant plus the CDK4/6 inhibitor or continue with standard treatment plus a placebo. The researchers found that it took 16 months for the disease to progress in women who got camizestrant, compared with 9.2 months in those who continued on standard therapy, a statistically significant difference in a measure known as progression-free survival. No new side effects were reported and few patients from either group dropped out due to side effects. "This is going to be very impactful for our patients," said Dr Hope Rugo, head of breast medical oncology at City of Hope in Duarte, California. The question, she said, is how do doctors incorporate the testing into clinical practice. Treating breast cancer patients with AstraZeneca's experimental pill camizestrant at the first sign of resistance to standard therapies cut the risk of disease progression or death by half, a finding that could be practice changing, experts say. The results, presented at the American Society of Clinical Oncology meeting in Chicago, mark the first use of a blood test called a liquid biopsy to indicate the need for a change in treatment in women with a common form of breast cancer, even before tumour growth can be detected on imaging. The early switch approach in women with hormone receptor-positive, HER2-negative breast cancer resulted in a 56 per cent reduction in the risk of disease progression or death, said Dr Eleonora Teplinsky, an oncologist at Valley-Mount Sinai Comprehensive Cancer Care and an ASCO breast cancer expert. "When patients progress on scans, we're already behind," Teplinsky said at a media briefing. She said an early switch approach, before disease progression, allows doctors "to essentially stay ahead of the curve." Camizestrant is not yet FDA-approved, but Teplinsky said she believes the data will likely result in a new treatment paradigm. The trial involved 3256 patients with advanced hormone receptor-positive, HER2-negative breast cancer, the most common type in which hormones such as oestrogen fuel cancer growth. These cancers lack high levels of HER2, another cancer driver. Women in the trial had at least six months of treatment with aromatase inhibitors that block hormones fueling the cancer, as well as targeted drugs called CDK4/6 inhibitors such as Novartis' Kisqali, Pfizer's Ibrance or Eli Lilly's Verzenio, which block an enzyme that fuels cancer growth. About 40 per cent of patients treated with aromatase inhibitors develop mutations in the oestrogen receptor 1 gene called ESR1 mutations, a sign of early drug resistance. Camizestrant and similar drugs called selective oestrogen receptor degraders, or SERDS, block oestrogen receptor signalling in cancer cells. In the trial, researchers used blood tests to identify 315 patients with signs of early drug resistance and then randomly assigned them to either switch to camizestrant plus the CDK4/6 inhibitor or continue with standard treatment plus a placebo. The researchers found that it took 16 months for the disease to progress in women who got camizestrant, compared with 9.2 months in those who continued on standard therapy, a statistically significant difference in a measure known as progression-free survival. No new side effects were reported and few patients from either group dropped out due to side effects. "This is going to be very impactful for our patients," said Dr Hope Rugo, head of breast medical oncology at City of Hope in Duarte, California. The question, she said, is how do doctors incorporate the testing into clinical practice. Treating breast cancer patients with AstraZeneca's experimental pill camizestrant at the first sign of resistance to standard therapies cut the risk of disease progression or death by half, a finding that could be practice changing, experts say. The results, presented at the American Society of Clinical Oncology meeting in Chicago, mark the first use of a blood test called a liquid biopsy to indicate the need for a change in treatment in women with a common form of breast cancer, even before tumour growth can be detected on imaging. The early switch approach in women with hormone receptor-positive, HER2-negative breast cancer resulted in a 56 per cent reduction in the risk of disease progression or death, said Dr Eleonora Teplinsky, an oncologist at Valley-Mount Sinai Comprehensive Cancer Care and an ASCO breast cancer expert. "When patients progress on scans, we're already behind," Teplinsky said at a media briefing. She said an early switch approach, before disease progression, allows doctors "to essentially stay ahead of the curve." Camizestrant is not yet FDA-approved, but Teplinsky said she believes the data will likely result in a new treatment paradigm. The trial involved 3256 patients with advanced hormone receptor-positive, HER2-negative breast cancer, the most common type in which hormones such as oestrogen fuel cancer growth. These cancers lack high levels of HER2, another cancer driver. Women in the trial had at least six months of treatment with aromatase inhibitors that block hormones fueling the cancer, as well as targeted drugs called CDK4/6 inhibitors such as Novartis' Kisqali, Pfizer's Ibrance or Eli Lilly's Verzenio, which block an enzyme that fuels cancer growth. About 40 per cent of patients treated with aromatase inhibitors develop mutations in the oestrogen receptor 1 gene called ESR1 mutations, a sign of early drug resistance. Camizestrant and similar drugs called selective oestrogen receptor degraders, or SERDS, block oestrogen receptor signalling in cancer cells. In the trial, researchers used blood tests to identify 315 patients with signs of early drug resistance and then randomly assigned them to either switch to camizestrant plus the CDK4/6 inhibitor or continue with standard treatment plus a placebo. The researchers found that it took 16 months for the disease to progress in women who got camizestrant, compared with 9.2 months in those who continued on standard therapy, a statistically significant difference in a measure known as progression-free survival. No new side effects were reported and few patients from either group dropped out due to side effects. "This is going to be very impactful for our patients," said Dr Hope Rugo, head of breast medical oncology at City of Hope in Duarte, California. The question, she said, is how do doctors incorporate the testing into clinical practice. Treating breast cancer patients with AstraZeneca's experimental pill camizestrant at the first sign of resistance to standard therapies cut the risk of disease progression or death by half, a finding that could be practice changing, experts say. The results, presented at the American Society of Clinical Oncology meeting in Chicago, mark the first use of a blood test called a liquid biopsy to indicate the need for a change in treatment in women with a common form of breast cancer, even before tumour growth can be detected on imaging. The early switch approach in women with hormone receptor-positive, HER2-negative breast cancer resulted in a 56 per cent reduction in the risk of disease progression or death, said Dr Eleonora Teplinsky, an oncologist at Valley-Mount Sinai Comprehensive Cancer Care and an ASCO breast cancer expert. "When patients progress on scans, we're already behind," Teplinsky said at a media briefing. She said an early switch approach, before disease progression, allows doctors "to essentially stay ahead of the curve." Camizestrant is not yet FDA-approved, but Teplinsky said she believes the data will likely result in a new treatment paradigm. The trial involved 3256 patients with advanced hormone receptor-positive, HER2-negative breast cancer, the most common type in which hormones such as oestrogen fuel cancer growth. These cancers lack high levels of HER2, another cancer driver. Women in the trial had at least six months of treatment with aromatase inhibitors that block hormones fueling the cancer, as well as targeted drugs called CDK4/6 inhibitors such as Novartis' Kisqali, Pfizer's Ibrance or Eli Lilly's Verzenio, which block an enzyme that fuels cancer growth. About 40 per cent of patients treated with aromatase inhibitors develop mutations in the oestrogen receptor 1 gene called ESR1 mutations, a sign of early drug resistance. Camizestrant and similar drugs called selective oestrogen receptor degraders, or SERDS, block oestrogen receptor signalling in cancer cells. In the trial, researchers used blood tests to identify 315 patients with signs of early drug resistance and then randomly assigned them to either switch to camizestrant plus the CDK4/6 inhibitor or continue with standard treatment plus a placebo. The researchers found that it took 16 months for the disease to progress in women who got camizestrant, compared with 9.2 months in those who continued on standard therapy, a statistically significant difference in a measure known as progression-free survival. No new side effects were reported and few patients from either group dropped out due to side effects. "This is going to be very impactful for our patients," said Dr Hope Rugo, head of breast medical oncology at City of Hope in Duarte, California. The question, she said, is how do doctors incorporate the testing into clinical practice.
Yahoo
3 days ago
- Business
- Yahoo
Blood test-guided treatment cuts breast cancer risk
Treating breast cancer patients with AstraZeneca's experimental pill camizestrant at the first sign of resistance to standard therapies cut the risk of disease progression or death by half, a finding that could be practice changing, experts say. The results, presented at the American Society of Clinical Oncology meeting in Chicago, mark the first use of a blood test called a liquid biopsy to indicate the need for a change in treatment in women with a common form of breast cancer, even before tumour growth can be detected on imaging. The early switch approach in women with hormone receptor-positive, HER2-negative breast cancer resulted in a 56 per cent reduction in the risk of disease progression or death, said Dr Eleonora Teplinsky, an oncologist at Valley-Mount Sinai Comprehensive Cancer Care and an ASCO breast cancer expert. "When patients progress on scans, we're already behind," Teplinsky said at a media briefing. She said an early switch approach, before disease progression, allows doctors "to essentially stay ahead of the curve." Camizestrant is not yet FDA-approved, but Teplinsky said she believes the data will likely result in a new treatment paradigm. The trial involved 3256 patients with advanced hormone receptor-positive, HER2-negative breast cancer, the most common type in which hormones such as oestrogen fuel cancer growth. These cancers lack high levels of HER2, another cancer driver. Women in the trial had at least six months of treatment with aromatase inhibitors that block hormones fueling the cancer, as well as targeted drugs called CDK4/6 inhibitors such as Novartis' Kisqali, Pfizer's Ibrance or Eli Lilly's Verzenio, which block an enzyme that fuels cancer growth. About 40 per cent of patients treated with aromatase inhibitors develop mutations in the oestrogen receptor 1 gene called ESR1 mutations, a sign of early drug resistance. Camizestrant and similar drugs called selective oestrogen receptor degraders, or SERDS, block oestrogen receptor signaling in cancer cells. In the trial, researchers used blood tests to identify 315 patients with signs of early drug resistance and then randomly assigned them to either switch to camizestrant plus the CDK4/6 inhibitor or continue with standard treatment plus a placebo. The researchers found that it took 16 months for the disease to progress in women who got camizestrant, compared with 9.2 months in those who continued on standard therapy, a statistically significant difference in a measure known as progression-free survival. No new side effects were reported and few patients from either group dropped out due to side effects. "This is going to be very impactful for our patients," said Dr Hope Rugo, head of breast medical oncology at City of Hope in Duarte, California. The question, she said, is how do doctors incorporate the testing into clinical practice.
West Australian
3 days ago
- Health
- West Australian
Blood test-guided treatment cuts breast cancer risk
Treating breast cancer patients with AstraZeneca's experimental pill camizestrant at the first sign of resistance to standard therapies cut the risk of disease progression or death by half, a finding that could be practice changing, experts say. The results, presented at the American Society of Clinical Oncology meeting in Chicago, mark the first use of a blood test called a liquid biopsy to indicate the need for a change in treatment in women with a common form of breast cancer, even before tumour growth can be detected on imaging. The early switch approach in women with hormone receptor-positive, HER2-negative breast cancer resulted in a 56 per cent reduction in the risk of disease progression or death, said Dr Eleonora Teplinsky, an oncologist at Valley-Mount Sinai Comprehensive Cancer Care and an ASCO breast cancer expert. "When patients progress on scans, we're already behind," Teplinsky said at a media briefing. She said an early switch approach, before disease progression, allows doctors "to essentially stay ahead of the curve." Camizestrant is not yet FDA-approved, but Teplinsky said she believes the data will likely result in a new treatment paradigm. The trial involved 3256 patients with advanced hormone receptor-positive, HER2-negative breast cancer, the most common type in which hormones such as oestrogen fuel cancer growth. These cancers lack high levels of HER2, another cancer driver. Women in the trial had at least six months of treatment with aromatase inhibitors that block hormones fueling the cancer, as well as targeted drugs called CDK4/6 inhibitors such as Novartis' Kisqali, Pfizer's Ibrance or Eli Lilly's Verzenio, which block an enzyme that fuels cancer growth. About 40 per cent of patients treated with aromatase inhibitors develop mutations in the oestrogen receptor 1 gene called ESR1 mutations, a sign of early drug resistance. Camizestrant and similar drugs called selective oestrogen receptor degraders, or SERDS, block oestrogen receptor signaling in cancer cells. In the trial, researchers used blood tests to identify 315 patients with signs of early drug resistance and then randomly assigned them to either switch to camizestrant plus the CDK4/6 inhibitor or continue with standard treatment plus a placebo. The researchers found that it took 16 months for the disease to progress in women who got camizestrant, compared with 9.2 months in those who continued on standard therapy, a statistically significant difference in a measure known as progression-free survival. No new side effects were reported and few patients from either group dropped out due to side effects. "This is going to be very impactful for our patients," said Dr Hope Rugo, head of breast medical oncology at City of Hope in Duarte, California. The question, she said, is how do doctors incorporate the testing into clinical practice.
Perth Now
3 days ago
- Health
- Perth Now
Blood test-guided treatment cuts breast cancer risk
Treating breast cancer patients with AstraZeneca's experimental pill camizestrant at the first sign of resistance to standard therapies cut the risk of disease progression or death by half, a finding that could be practice changing, experts say. The results, presented at the American Society of Clinical Oncology meeting in Chicago, mark the first use of a blood test called a liquid biopsy to indicate the need for a change in treatment in women with a common form of breast cancer, even before tumour growth can be detected on imaging. The early switch approach in women with hormone receptor-positive, HER2-negative breast cancer resulted in a 56 per cent reduction in the risk of disease progression or death, said Dr Eleonora Teplinsky, an oncologist at Valley-Mount Sinai Comprehensive Cancer Care and an ASCO breast cancer expert. "When patients progress on scans, we're already behind," Teplinsky said at a media briefing. She said an early switch approach, before disease progression, allows doctors "to essentially stay ahead of the curve." Camizestrant is not yet FDA-approved, but Teplinsky said she believes the data will likely result in a new treatment paradigm. The trial involved 3256 patients with advanced hormone receptor-positive, HER2-negative breast cancer, the most common type in which hormones such as oestrogen fuel cancer growth. These cancers lack high levels of HER2, another cancer driver. Women in the trial had at least six months of treatment with aromatase inhibitors that block hormones fueling the cancer, as well as targeted drugs called CDK4/6 inhibitors such as Novartis' Kisqali, Pfizer's Ibrance or Eli Lilly's Verzenio, which block an enzyme that fuels cancer growth. About 40 per cent of patients treated with aromatase inhibitors develop mutations in the oestrogen receptor 1 gene called ESR1 mutations, a sign of early drug resistance. Camizestrant and similar drugs called selective oestrogen receptor degraders, or SERDS, block oestrogen receptor signaling in cancer cells. In the trial, researchers used blood tests to identify 315 patients with signs of early drug resistance and then randomly assigned them to either switch to camizestrant plus the CDK4/6 inhibitor or continue with standard treatment plus a placebo. The researchers found that it took 16 months for the disease to progress in women who got camizestrant, compared with 9.2 months in those who continued on standard therapy, a statistically significant difference in a measure known as progression-free survival. No new side effects were reported and few patients from either group dropped out due to side effects. "This is going to be very impactful for our patients," said Dr Hope Rugo, head of breast medical oncology at City of Hope in Duarte, California. The question, she said, is how do doctors incorporate the testing into clinical practice.
